BCG

BCG-medac, powder and solvent for suspension for intravesical use

BCG (Bacillus Calmette Guérin) is indicated for the treatment of non-invasive urothelial bladder carcinoma:

• curative treatment of carcinoma in situ
• prophylactic treatment of recurrence of :
  • urothelial carcinoma limited to mucosa :
    • Ta G1-G2 if multifocal and/or recurrent tumour
    • Ta G3
  • urothelial carcinoma in lamina propria but not the muscular of the bladder (T1)
  • carcinoma in situ

The active ingredient is BCG (Bacillus Calmette Guérin) bacteria seed RIVM derived from seed 1173-P2 2 x 108 to 3 x 109 viable units

This product is available in the following presentations:

• Powder & Solution for suspension for intravesical use in 50ml bag

It is available in the Republic of  Ireland from Fannin Ltd in partnership with Medac. (This link will take you to a non-Fannin Ltd. website.  Fannin Ltd. does not recommend, endorse or accept liability for sites controlled by third-parties).

For a copy of the SPC please click here.

Method of Sale: POM

PA Number: PA 0623/004/001

MAH Holder: medac Gesellschaft für klinische Spezialpräparate mbH Theaterstr. 6 22880 Wedel Germany

DHPC BCG Information

For additional information please contact our medical information department at medical@dccvital.com or via phone on 01 2907000

Additional information available on request.

Date of preparation: July 2018

IE2018/086/00